Can I read T-cell Interleukin-6 Receptor Binding in Interferon-β-1b-treated Multiple Sclerosis Patients on EtoBox?

T-cell Interleukin-6 Receptor Binding in Interferon-β-1b-treated Multiple Sclerosis Patients by P. Bongioanni; F. Lombardo; G. Moscato; S. Mosti; G. Meucci is a Medicine article available to read on EtoBox.

What is T-cell Interleukin-6 Receptor Binding in Interferon-β-1b-treated Multiple Sclerosis Patients about?

Multiple sclerosis (MS) is a T-cell-mediated autoimmune demyelinating disease of the central nervous system, associated with an altered cytokine network. We previously assayed peripheral blood T-lymphocyte binding for two prototypic cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and found that T cells from MS patients had significantly more TNF-alpha and IL-6 receptors than those from healthy controls. In the present work, paralleling a previous one on T-cell TNF-alpha binding, we studied the effect of interferon (IFN)-beta-1b treatment on T-lymphocyte IL-6 binding in patients with relapsing-remitting MS. T cells from MS patients had significantly (P < 0.001) higher amounts of IL-6 receptors than those from controls [292 +/- 6 vs. 228 +/- 8 (mean +/- SEM) receptors per cell, respectively], whereas the ligand-receptor affinity values were similar in the two groups [26.2 +/- 0.7 and 25.7 +/- 0.4 (mean +/- SEM) pmoles/l, respectively]. After a 3-month IFN-beta-1b treatment, they showed a significant decrease in IL-6 binding [266 +/- 7 (mean +/- SEM) receptors per cell]. After 6 and 9 months, T-cell IL-6 B(max) values were even lower [258 +/- 8 and 251 +/

Who reads T-cell Interleukin-6 Receptor Binding in Interferon-β-1b-treated Multiple Sclerosis Patients?

Author

P. Bongioanni; F. Lombardo; G. Moscato; S. Mosti; G. Meucci

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 1351-5101)

Published

2001

Language

EN

Field

Medicine (Health Sciences)